Vanda Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs. The company's commercial portfolio includes HETLIOZ (tasimelteon) for non-24-hour sleep-wake disorder, Fanapt (iloperidone) for schizophrenia and bipolar I disorder, and PONVORY (ponesimod) for multiple sclerosis. Vanda is also actively launching NEREUS (tradipitant) for motion sickness, marking the first new prescription treatment for this condition in over 40 years.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Launching NEREUS™ (tradipitant) nationwide through an innovative direct-to-consumer platform (nereus.us). This patient-centric model enables convenient online ordering and rapid direct home delivery, bypassing traditional pharmacy barriers.
Expected impact: Expected to generate $10 million to $30 million in net product sales in 2026 and establish a modern, seamless access model for prescription therapies.
Preparing for the commercial availability of BYSANTI™ (milsaperidone) in the back half of 2026 following its FDA approval in February 2026. The initiative aims to capture share in the global antipsychotic category, which has an estimated addressable market of $20 billion.
Expected impact: Aims to drive long-term growth alongside Fanapt and contribute to a target of $750 million for the psychiatry portfolio by 2030.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Acquired exclusive global rights to develop and commercialize imsidolimab (an IL-36R antagonist mAb). This transaction adds a late-stage asset with successful Phase 3 trials (GEMINI-1 and GEMINI-2) to Vanda's rare orphan and anti-inflammatory portfolio.
Terms: Vanda paid an upfront payment of $10 million and $5 million for existing drug supply. AnaptysBio is eligible to receive up to $35 million in future regulatory and sales milestones, plus a 10% royalty on global net sales.